| EPIC |
HLN |
| Sector |
Pharma and Biotech |
| ISIN |
GB00BMX86B70 |
| Market Sector |
MAIN |
| Market Segment |
SET1 |
| Main Indices |
FTSE 100, FTSE 350, FTSE All-Share |
| Country of register |
Great Britain |
| Currency |
British Pound |
| Market Cap |
£33,382m |
| NMS |
7,500 |
| Shares in issue |
8,906m |
| Date Listed |
n/a |
| |
Interim |
Final |
| Ex-Div |
14-Aug-25 |
24-Apr-25 |
| Paid |
18-Sep-25 |
05-Jun-25 |
| Amount |
2.20p |
4.60p |
| 12:37 |
3,119 @ 374.80p |
| 12:37 |
27,346 @ 374.80p |
| 12:35 |
673 @ 374.80p |
| 12:35 |
3,291 @ 374.80p |
| 12:35 |
5,379 @ 374.80p |
| CEO |
Brian McNamara |
| Chair |
Manvinder Singh (Vindi) Banga |
| CFO |
Dawn Allen |
Top of Page
You are here:
research